ESTUTC-5 New YorkLog in Sign up

ADCT
ADC Therapeutics SA
stockNYSE

Market OpenNov 13, 2026 2:19:30 PM EST

1.39USD-1.064%(-0.02)759,209

Pre-marketNov 13, 2026 9:20:30 AM EST

1.41USD0.000%(0.00)

1.3900Bid1.4100Ask0.0200Spread

ADCT News

Day breaks

06:25 PM ESTADC Therapeutics at guggenheim healthcare conference: data and runway improve ·

Investing.com

11:25 AM ESTADC Therapeutics earnings beat by $0.05, revenue topped estimates ·

Investing.com

10:01 AM ESTADC Therapeutics Reports Q3 2026 Earnings: GAAP EPS at $-0.16, Revenue at $21. ... ·

GuruFocus

07:53 AM ESTADC Therapeutics Q3 Product Revenue Totals $21 Million as Loss Narrows ·

Securities.io

07:43 AM ESTADC Therapeutics Non-GAAP EPS of -$0.06, revenue of $21M beats by $1.93M ·

Seeking Alpha

07:30 AM ESTADC Therapeutics Reports Third Quarter 2026 Financial Results and Provides Operational Updates ·

PR Newswire

11:14 PM ESTADC Therapeutics SA (ADCT) Discusses ZYNLONTA Data at ASH and Strategic Financial Restructuring Transcript ·

Seeking Alpha

07:15 AM ESTADC Therapeutics to Present at November Investor Conferences ·

PR Newswire

04:05 PM ESTADC Therapeutics Announces New Employee Inducement Grant ·

PR Newswire

07:15 AM ESTADC Therapeutics to Announce Third Quarter 2026 Financial Results on November 9, 2026 ·

PR Newswire

07:36 AM EDTADC Therapeutics partner files for Japan approval of ZYNLONTA ·

Investing.com

07:30 AM EDTADC Therapeutics Announces ZYNLONTA® Updates in Japan ·

PR Newswire

11:23 AM EDTADC Therapeutics undergoes strategic financial restructuring ·

Seeking Alpha

09:12 AM EDTADC Therapeutics secures $86.6M financing, restructures debt ·

Investing.com

10:00 AM EDTStrategic Collaboration | Sanyou Bio and NovoCodex Partner to Co-Develop Innovative Dual-Payload ADCs ·

PR Newswire